Lite Strategy, Inc. (LITS): Total Liabilities
$1.35M
As of 2025-06-30
$952.0K
As of 2026-03-31
-77.9%
3-year compound annual growth
-60.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $1.35M | -83.8% | 2025-09-26, Balance as of period end |
| 2024-06-30 | $8.36M | -91.3% | 2025-09-26, Balance as of period end |
| 2023-06-30 | $96.19M | -23.3% | 2024-09-19, Balance as of period end |
| 2022-06-30 | $125.43M | +0.6% | 2023-09-26, Balance as of period end |
| 2021-06-30 | $124.63M | -6.1% | 2022-09-08, Balance as of period end |
| 2020-06-30 | $132.67M | +282.0% | 2022-05-23, Balance as of period end |
| 2019-06-30 | $34.73M | -35.9% | 2020-09-09, Balance as of period end |
| 2018-06-30 | $54.20M | n/m | 2019-08-28, Balance as of period end |
| 2017-06-30 | $4.87M | n/a | 2018-08-30, Balance as of period end |
| No annual figure between 2012-06-30 and 2017-06-30. | |||
| 2012-06-30 | $1.77M | -25.3% | 2012-09-18, Balance as of period end |
| 2011-06-30 | $2.37M | n/a | 2012-09-18, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | 2025-06-30 | $1.35M | -83.8% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Procyon Corp (PCYN) | 2024-06-30 | $917.1K | -3.1% |
Compare LITS, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗